To include your compound in the COVID-19 Resource Center, submit it here.

Denali grants Takeda options to neurology antibodies

Denali Therapeutics Inc. (NASDAQ:DNLI) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) options to co-develop and co-commercialize neurodegenerative disorder candidates ATV:BACE1/Tau, ATV:TREM2 and an undisclosed discovery-stage program.

The biotech is to receive $40 million

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE